ATXN7L1 Activators are a diverse group of chemical compounds that indirectly boost the functional activity of ATXN7L1 through various signaling pathways and molecular mechanisms. Forskolin and Rolipram both raise intracellular cAMP levels, with Forskolin directly stimulating adenylate cyclase and Rolipram inhibiting PDE4. The increased cAMP activates PKA, which is known to phosphorylate a variety of proteins, potentially including ATXN7L1, thereby enhancing its functional role. Ionomycin, by increasing calcium concentrations within the cell, could also augment ATXN7L1 function by affecting calcium-dependent kinases that might phosphorylate ATXN7L1. Similarly, TPA, as a PKC activator, initiates a cascade that may indirectly enhance ATXN7L1's function in chromatin remodeling. Meanwhile, natural compounds like Curcumin and Resveratrol modulate NF-κB and SIRT1 pathways, respectively, potentially affecting ATXN7L1's role in gene expression regulation. EGCG, through its inhibition of kinases within the MAPK pathway, could lead to a signaling environment that favors ATXN7L1's activity.
Further indirect activation of ATXN7L1 comes from compounds that influence cellular homeostasis and stress response. SSpermidine enhances autophagy by inhibiting EP300, which may have implications for ATXN7L1's function in the maintenance of protein quality. LY294002 disrupts PI3K/AKT signaling, possibly impacting ATXN7L1's role in downstream signal transduction processes. The inhibition of p38 MAPK by SB203580 might shift signaling dynamics to pathways where ATXN7L1 is more actively involved, particularly in cellular responses to stress. Okadaic acid, through its inhibition of phosphatases PP1 and PP2A, may lead to a hyperphosphorylated state of cellular proteins, thereby indirectly enhancing the activity of ATXN7L1 if it is a substrate for these phosphatases. Lastly, Trichostatin A impacts chromatin accessibility and gene expression by inhibiting histone deacetylases, which could lead to an environment that supports the transcriptional regulatory functions of ATXN7L1. Collectively, these ATXN7L1 Activators, by targeting different aspects of cellular signaling and gene regulation, contribute to the enhancement of ATXN7L1-mediated cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cAMP levels. Elevated cAMP enhances protein kinase A (PKA) activity, which can phosphorylate ATXN7L1, possibly increasing its functional activity in processes such as transcription regulation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to an accumulation of cAMP in cells. This can indirectly enhance the activity of ATXN7L1 through PKA-mediated phosphorylation pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can modulate calcium-dependent protein kinases and potentially enhance the phosphorylation and activity of ATXN7L1. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
TPA activates protein kinase C (PKC), which can lead to downstream signaling effects that may enhance ATXN7L1 activity, potentially influencing its role in chromatin remodeling. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is a modulator of the NF-κB pathway, which could indirectly influence ATXN7L1 by altering the transcriptional regulation of genes that interact with or modify ATXN7L1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol activates the SIRT1 pathway, which is involved in histone deacetylation. This activation may indirectly enhance ATXN7L1 activity through modifications in chromatin structure. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits multiple kinases and has been shown to modulate signaling pathways such as MAPK, which might lead to altered activity of ATXN7L1 due to changes in the phosphorylation state of proteins within these pathways. | ||||||
Spermidine | 124-20-9 | sc-215900 sc-215900B sc-215900A | 1 g 25 g 5 g | $57.00 $607.00 $176.00 | ||
Spermidine promotes autophagy through the inhibition of the acetyltransferase EP300, which could enhance the degradation of misfolded or aggregated proteins, potentially affecting ATXN7L1 function in protein quality control. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter downstream AKT signaling, possibly leading to modified interactions or activity of ATXN7L1 in signal transduction pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may shift the balance of cellular signaling pathways, potentially influencing ATXN7L1 activity in response to stress stimuli. | ||||||